- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05923047
Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study. (MELYSA)
This randomized, controlled multicenter trial will recruit patients aged 18 to 70 7 years with recurrent nasal polyposis requiring surgery and indication for biologic treatment according to EPOS 2020 guideline. Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment.
All study procedures will be performed in five study visits and may take approximately 30 minutes. Clinical assessments include different questionnaires and nasal endoscopy. This trial includes three treatment arms.
- Combined group (In-office nasal polypectomy group with mepolizumab): This group will undergone in-office nasal polypectomy and will receive Mepolizumab.
- Medical group (mepolizumab): This group will receive Mepolizumab.
- Surgical group (In-office nasal polypectomy): This group will undergone in-office nasal polypectomy. The main advantage is that it allows comparison of mepolizumab versus surgery and surgery/mepolizumab versus surgery + mepolizumab, providing more information on the most effective therapeutic approach.
The presence of adverse effects will be assessed in each treatment arm.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bilbao, Spain
- Hospital de Curces
-
Contact:
- Francisco Valcarcel
-
Jerez De La Frontera, Spain
- Hospital de Jerez
-
Contact:
- Alfonso cuvillo
-
Madrid, Spain
- Hospital Puerta del Hierro
-
Contact:
- Antonio Martinez
-
Oviedo, Spain
- HUCA
-
Contact:
- Jose Luis Llorente
-
Santander, Spain, 39011
- Hospital Universitario Marques de Valdecilla
-
Contact:
- david Lobo
- Email: david.lobo@scsalud.es
-
Sevilla, Spain
- Hospital Virgen Macarena
-
Contact:
- serafin sanchez
-
Valladolid, Spain
- Hospital Valladolid
-
Contact:
- Jaime santos
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant 18 years of age or older
- Patients with a diagnosis of CRS with polyposis according to the criteria of the EPOS2020 guideline:
Chronic rhinosinusitis with nasal polyps in adults is defined as presence of two or more symptoms, one of which should be either nasal blockage / obstruction / congestion or nasal discharge (anterior / posterior nasal drip); ± facial pain/pressure; ± reduction or loss of smell; for ≥12 weeks; and either endoscopic signs of nasal polyps, and/or CT changes: mucosal changes within the ostiomeatal complex and/or sinuses.
- Patients with indication for biologic treatment according to the criteria of the EPOS2020 guideline. Presence of bilateral polyps in a patient who had ESS (except in cases where the patient is not fit for surgery, see bellow) and three of the following criteria are required:
- Evidence of type 2 inflammation (tissue eos> 10/hpf* or blood eos>250, OR total IgE> 100).
- Need for systemic corticosteroids or contraindication to systemic steroids (≥ 2 courses per yr, OR long term (>3 months)
- Significantly impaired quality of life (SNOT ≥ 40)
- Significant loss of smell (≥7 VAS)
- Diagnosis of comorbid asthma
- Basal eosinophil count (BEC) ≥300 cells/μL for surgical naïve patients- only those not fit for surgery (major criteria) or for those who have had surgery and have recurrence (minor criteria).
- Patients have been informed and signed consent to participate in the study.
- For those patients not suitable for surgery, the criteria of the EUFOREA guidelines for indication of biological treatment will be used (4 criteria, one of them being ≥300 cells/μL BEC).
Exclusion Criteria:
- Any serious or uncontrolled systemic or psychiatric illness that prevents a correct cognitive or endoscopic assessment or does not advise participation in the study.
- Unilateral localized secondary CRS (odontogenic, fungal ball, tumor).
- Bilateral diffuse secondary CRS (cystic fibrosis; eosinophilic granulomatosis with polyangiitis-S. de Churg-Strauss-; granulomatosis with polyangiitis-S de Wegener-; primary ciliary dyskinesia; selective immunodeficiencies.
- Pregnancy/ breast feeding
- Hypersensitivity to mepolizumab or it's excipients
- Patients unable to complete the questionnaire or follow prescribed treatment.
- Patients who are participating in another clinical trial related to polyposis or asthma.
- Previously documented failure with IL-5/IL-5 receptor biologics
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combined group
In-office nasal polypectomy group with mepolizumab
|
Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment
|
Experimental: Medical group
(mepolizumab)
|
Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment
|
Active Comparator: Surgical group
In-office nasal polypectomy
|
This group will undergone in-office nasal polypectomy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mepolizumab+polypectomy compared to mepolizumab or polypectomy, using the change from baseline in sinonasal outcome test (SNOT-22) total score
Time Frame: up to 52 weeks
|
up to 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in nasal polyposis severity VAS score at 4 weeks, 6 months, 12 months
Time Frame: up to 52 weeks
|
up to 52 weeks
|
|
Change in endoscopic nasal polyp score at 4 weeks, 6 months, 12 months
Time Frame: up to 52 weeks
|
up to 52 weeks
|
|
Improvement in individual VAS symptoms (rhinorrhea, mucus in throat, nasal blockage, and sense of smell), patient-reported outcomes at 4 weeks, 6 months, 12 months
Time Frame: up to 52 weeks
|
up to 52 weeks
|
|
Number of patients no longer requiring rescue systemic corticosteroid treatment throughout the first year after the first month of starting the study
Time Frame: up to 52 weeks
|
up to 52 weeks
|
|
Number of participants with mepolizumab and in-office nasal polypectomy related adverse events
Time Frame: up to 52 weeks
|
up to 52 weeks
|
|
Change from baseline in sinonasal outcome test
Time Frame: up to 4 and 24 week
|
The minimum value is 0 and maximum value is 110
|
up to 4 and 24 week
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IDIVAL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rhinosinusitis Chronic
-
Unity Health TorontoCompletedChronic RhinosinusitisCanada
-
University of MiamiCompleted
-
Medtronic Surgical TechnologiesCompleted
-
University of MichiganNeilMed PharmaceuticalsCompletedChronic RhinosinusitisUnited States
-
Odense University HospitalCompleted
-
Taichung Veterans General HospitalCompletedPostoperative Care | Chronic RhinosinusitisTaiwan
-
Christiane HaaseActive, not recruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsDenmark
-
Washington University School of MedicineCompletedChronic Rhinosinusitis (Diagnosis) | Allergic Rhinosinusitis | Chronic Eosinophilic RhinosinusitisUnited States
-
Icahn School of Medicine at Mount SinaiTivic Health SystemsRecruiting
Clinical Trials on Mepolizumab
-
GlaxoSmithKlineCompletedAsthmaUnited States, Argentina, Australia, Germany, Poland, Romania, Russian Federation, Ukraine, Canada, Chile, France, Korea, Republic of, United Kingdom
-
Academisch Medisch Centrum - Universiteit van Amsterdam...GlaxoSmithKline; The Netherlands Asthma FoundationUnknownAsthma | Viral InfectionNetherlands
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingChronic Rhinosinusitis With Nasal PolypsItaly
-
GlaxoSmithKlineRecruitingEosinophilic Granulomatosis With PolyangiitisCanada, France, Italy, Spain, Belgium, Korea, Republic of, United States, Japan, China, Czechia, Hungary, Israel, Portugal, Poland, Netherlands, United Kingdom, Austria, Argentina, Australia, Brazil, Germany, Sweden
-
GlaxoSmithKlineCompletedAsthmaUnited States, Argentina, Australia, Canada, France, Germany, Japan, Russian Federation, Spain, Ukraine, Belgium, Chile, Korea, Republic of, Mexico, Italy, United Kingdom
-
St. Paul's Sinus CentreNot yet recruiting
-
Policlinico Universitario, CataniaRecruitingBronchiectasis | Bronchial AsthmaItaly
-
GlaxoSmithKlineRecruitingHypereosinophilic SyndromeUnited States, Argentina, Spain, Turkey, Israel, Brazil, Mexico, United Kingdom
-
GlaxoSmithKlineCompletedHypereosinophilic Syndrome | HypereosinophiliaUnited States, Belgium, Canada, Germany, Italy, France, Switzerland, Australia
-
GlaxoSmithKlineCompletedAsthmaJapan, United States, United Kingdom, Poland